Nidek Oxygen Concentrator Recall Issued Due to Fire Risk
Federal health regulators are warning that problems with Nidek Medical Products’ Nuvo series of Oxygen Concentrators could lead to serious injury or death.
The FDA announced on June 21 that it was classifying a Nidek oxygen concentrator recall as a class 1 medical device recall.
The oxygen concentrators, which supply supplemental oxygen to patients at home, have been deemed a fire hazard and have been given the most serious categorization, suggesting that use of the device carries a high probability of someone being severely injured or killed by a fire sparked by one of the devices, or due to the resulting loss of supplemental oxygen
Did You Know? Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
According to Nidek’s recall press release, the Mark 5 Nuvo series of concentrators have a capacitor component which can fail and has caused fires in residential and nursing homes. However, there have been no injuries associated with the fires or failed oxygen concentrators to date.
The recall affects certain models of the Nidek Medical Mark5 Nuvo, Nuvo 8 and Nuvo Lite Oxygen Concentrators. The affected oxygen concentrators were manufactured between January 1, 2004 and May 15, 2010. They have serial numbers ranging from 042-10000 through 102-09335.
According to Nidek, the company is in the process of notifying all distributors and customers about the recall through both email and regular mail and has reached the owners of 95% of the affected devices.
The FDA recommends that consumers notify their equipment provider if they have an affected product in their home or place of business. The company has said they can continue to use the device while waiting for a replacement for the defective capacitor.
Consumers with questions can call Nidek Medical Products, Inc. at 1-2050856-7200 ext 242, or can contact the company by email at email@example.com.
"*" indicates required fields
More Top Stories
The President has signed the Camp Lejeune Justice Act into law as part of a larger package of veterans toxic chemical exposure health care benefits, which will allow those exposed to water contamination while living or serving on the base to file lawsuits against the federal government.
Ahead of the first Zantac lawsuit trials, slated to begin next year, investors sold off Sanofi, GlaxoSmithKline and Pfizer stocks, anticipating massive court losses and costs.
A federal judge has issued a pretrial scheduling order setting the first Nexium kidney damage lawsuit to go before a jury in November.